SHAREHOLDER ALERT: The Law Offices of Timothy L. Miles Announces Exicure, Inc. (XCUR) Sued for Misleading Shareholders

Paraquat Lawyer Timothy L. Miles of Nashville Named a 2021 Elite Lawyer

Timothy L. Miles Named a 2021 Top Rated Lawyer

LOGI

Nationally Recognized Shareholder Rights Attorney Timothy L. Miles

LOGO

Nationally Recognized Shareholder Rights Attorney Timothy L. Miles

Nationally Recognized Shareholder Rights Attorney Timothy L. Miles

Nationally Recognized Shareholder Rights Attorney Timothy L. Miles Has Achieved the Recognition of American’s Mo

Exicure, Inc. (XCUR) is Being Sued for Misleading Shareholders

Exicure, Inc. (NASDAQ:XCUR)

HENDERSONVILLE, TN, UNITED STATES, December 23, 2021 /EINPresswire.com/ -- The Law Offices of Timothy L. Miles, who has been leading the fight to protect shareholder rights for over 20 years, announces announces that a purchaser of Exicure, Inc. (XCUR) filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities Exchange Act of 1934 between March 11, 2021 and November 15, 2021. Exicure is a clinical stage biotechnology company that develops therapeutics for neurology, immune-oncology, inflammatory diseases, and other genetic disorders based on its proprietary spherical nucleic acid technology. The Exicure class action lawsuit was commenced on December 13, 2021 in the Northern District of Illinois and is captioned Colwell v. Exicure, Inc., No. 21-cv-06637.

If you suffered a loss due to XCUR, Inc.'s misconduct, click here.

Exicure Misled Investors Regarding its Business Operations

A class action was filed on behalf of all persons and entities that purchased or otherwise acquired Exicure, Inc. (NASDAQ: XCUR) securities between March 11, 2021 and November 15, 2021, for violations of the Securities Exchange Act of 1934. Exicure is a clinical stage biotechnology company that develops therapeutics for neurology, immune-oncology, inflammatory diseases, and other genetic disorders based on its proprietary spherical nucleic acid technology.

According to the complaint, defendants failed to disclose that there had been certain improprieties in Exicure’s preclinical program for the treatment of Friedreich’s ataxia and that there was a material risk that data from the preclinical program would not support continued clinical development.

On November 15, 2021, Exicure filed a Form 12b-25 with the SEC stating that it could not timely file its quarterly report ended September 30, 2021. It explained it was investigating “a claim made by a former Company senior researcher regarding alleged improprieties that researcher claims to have committed with respect to the Company’s XCUR-FXN preclinical program for the treatment of Friedreich’s ataxia.” On this news, the Company’s stock price fell 28%, to close at $1.07 per share on November 16, 2021. The stock trades even lower today.

If you acquired shares of Exicure, Inc. (XCUR) securities between March 11, 2021 and November 15, 2021, you have until February 11, 2022, to ask the court to appoint you lead plaintiff for the class.

Exicure Shareholders Urged to Contact the Firm

If you purchased Exicure securities, have information, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Timothy L. Miles, Esquire, at 615-587-7384, Toll-Free at 855-846-6529, or by email to tmiles@timmileslaw.com or click here and submit a form. If you inquire by email please include your mailing address, telephone number, and the number shares owned.

About Timothy L. Miles
Timothy L. Miles is a nationally recognized shareholder, employee rights and personal injury attorney raised in Nashville, Tennessee. Earlier this year, Mr. Miles was recognized as a 2021 Top Ranked Lawyer; 2021 Top Rated Litigator; and a 2021 Elite Lawyer of The South by Martindale-Hubbell® and ALM, his third consecutive year to receive each award. Mr. Miles also maintains the AV Preeminent Rating by Martindale-Hubbell®, their highest rating for both legal ability and ethics. Mr. Miles is a member of the prestigious Top 100 Civil Plaintiff Trial Lawyers: The National Trial Lawyers Association, a superb rated attorney by Avvo, a recipient of the Lifetime Achievement Award by Premier Lawyers of America (2019) and recognized as a Distinguished Lawyer, Recognizing Excellence in Securities Law, by Lawyers of Distinction (2019). Awards: Top Rated Litigator by Martindale-Hubbell® and ALM (2019-2021); Top Rated Lawyer by Martindale-Hubbell® and ALM (2019-2021); Elite Lawyer of The South by Martindale-Hubbell® and ALM (2019-2021); Member of the Top 100 Civil Plaintiff Trial Lawyers: The National Trial Lawyers Association (2017-2021); AV® Preeminent™ Rating by Martindale-Hubble® (2014-2021); PRR AV Preeminent Rating on Lawyers.com (2018-2021); The Top-Rated Lawyer in Litigation™ for Ethical Standards and Legal Ability (Martindale-Hubble® 2015); Lifetime Achievement Award by Premier Lawyers of America (2019); Distinguished Lawyer, Recognizing Excellence in Securities Law, by Lawyers of Distinction (2019-2021); Superb Rated Attorney (Avvo); Avvo Top Rated Lawyer for (Avvo 2017-2020). Mr. Miles has authored numerous publications advocating for shareholdings including most recently: Free Portfolio Monitoring Services Offered by Plaintiff Securities Firms Provides Significant Benefits to Investors (Timothy L. Miles, Dec. 3, 2019).

CONTACT:
Timothy L. Miles, Esq.
Law Offices of Timothy L. Miles
141 Saundersville Road, #2202
Hendersonville, TN 37075
Telephone: (855-846-6529)
Email: tmiles@timmileslaw.com
Website: www.timmileslaw.com
Case Website:

Timothy L. Miles
Law Offices of Timothy L. Miles
+1 6155877384
email us here
Visit us on social media:
Facebook
LinkedIn
Other

Timothy Lee. Miles
Law Offices Of Timothy L. Miles
+1 615-587-7384
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn
Other

Leave a comment